Protagonist Therapeutics Inc banner

Protagonist Therapeutics Inc
NASDAQ:PTGX

Watchlist Manager
Protagonist Therapeutics Inc Logo
Protagonist Therapeutics Inc
NASDAQ:PTGX
Watchlist
Price: 98.51 USD -1.49% Market Closed
Market Cap: $6.3B

Protagonist Therapeutics Inc
Long-Term Investments

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Protagonist Therapeutics Inc
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Protagonist Therapeutics Inc
NASDAQ:PTGX
Long-Term Investments
$78.6m
CAGR 3-Years
N/A
CAGR 5-Years
108%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Long-Term Investments
$268m
CAGR 3-Years
4%
CAGR 5-Years
-2%
CAGR 10-Years
6%
Gilead Sciences Inc
NASDAQ:GILD
Long-Term Investments
$3B
CAGR 3-Years
34%
CAGR 5-Years
43%
CAGR 10-Years
-13%
Amgen Inc
NASDAQ:AMGN
Long-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Long-Term Investments
$5.7B
CAGR 3-Years
287%
CAGR 5-Years
207%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Long-Term Investments
$10.3B
CAGR 3-Years
16%
CAGR 5-Years
26%
CAGR 10-Years
32%
No Stocks Found

Protagonist Therapeutics Inc
Glance View

Market Cap
6.3B USD
Industry
Biotechnology

Protagonist Therapeutics Inc. stands as a pioneering player in the biopharmaceutical landscape, diligently orchestrating the journey from scientific discovery to therapeutic breakthroughs. Established with the vision to exploit the therapeutic potential of peptides, the company has carved a niche for itself by focusing on innovative peptide-based drug discovery and development. Their proprietary technology platform is designed to genetically engineer and optimize peptides aimed at treating a spectrum of diseases, notably in areas of unmet medical needs such as autoimmune conditions and rare genetic disorders. The fusion of cutting-edge biotechnology and seasoned expertise enables Protagonist to transform promising scientific concepts into viable medicines, paving the way for advancements in patient treatment options. Fueling its growth and revenue potential, Protagonist Therapeutics operates primarily through partnerships and collaborative alliances, as well as progressing its proprietary pipeline. By leveraging strategic collaborations with established pharmaceutical giants, the company garners funding, technological insights, and broader developmental capabilities. This collaborative synergy not only bolsters their research endeavors but also hastens the clinical development and eventual commercialization of their pipeline products. Their ability to secure partnerships and effectively progress their drug candidates through various clinical stages is critical to their financial model, converting scientific innovation into shareholder value and societal impact. The company continues to navigate the complexities of drug development with a steadfast focus on unlocking the therapeutic potential of peptides, aspiring to merge innovation with tangible health benefits.

PTGX Intrinsic Value
12.83 USD
Overvaluation 87%
Intrinsic Value
Price $98.51

See Also

What is Protagonist Therapeutics Inc's Long-Term Investments?
Long-Term Investments
78.6m USD

Based on the financial report for Dec 31, 2025, Protagonist Therapeutics Inc's Long-Term Investments amounts to 78.6m USD.

What is Protagonist Therapeutics Inc's Long-Term Investments growth rate?
Long-Term Investments CAGR 5Y
108%

Over the last year, the Long-Term Investments growth was -44%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett